Linagliptin and Newer DPP-4 Inhibitors: Newer Uses and Newer Indications

Title: Linagliptin and Newer DPP-4 Inhibitors: Newer Uses and Newer Indications

Volume: 5 Issue: 3

Author(s): Sanjay Kalra, Ambika G. Unnikrishnan, Navneet Agrawal and Anupam K. Singh

Affiliation:

Keywords: Diabetes, Pharmacokinetics, placebo, DPP4 inhibitors, hepatic safety, incretins, linagliptin, oral hypoglycemics, multiple sclerosis, renal safety

Abstract: The dipeptidyl peptidase-4 (DPP-4) inhibitors linagliptin, sitagliptin, saxagliptin, vildagliptin and alogliptin are being developed and have been approved for the treatment of type-2 diabetes. These agents may be used either as monotherapy for the treatment of type-2 diabetes or in combination with other anti-diabetic drugs. The present review highlights the use of linagliptin and other new (DPP-4) inhibitors in the management of type-2 diabetes. The review also highlights advantages, comparative pharmacokinetic, safety profile and other potential uses including potential newer indications of DPP-4 inhibitors and relevant patents. The other potential uses that are not restricted to diabetes include obesity, cardiovascular disease, neurological disease, hepatobiliary disease, wound healing, and other inflammatory illnesses.

Cite this article as:

Kalra Sanjay, G. Unnikrishnan Ambika, Agrawal Navneet and K. Singh Anupam, Linagliptin and Newer DPP-4 Inhibitors: Newer Uses and Newer Indications, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) 2011; 5 (3) . https://dx.doi.org/10.2174/187221411797265926